Not Yet RecruitingPhase 2ACTRN12606000099527
An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Renal Cell Carcinoma
Sponsor
Solbec Pharmaceuticals Ltd
Enrollment
56 participants
Start Date
Jun 30, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying: An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Renal Cell Carcinoma. It may be open to adults aged 18 and older who meet certain criteria, including: Histologically confirmed diagnosis of non-resectable clear cell or papillary type Renal Cell Carcinoma. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Coramsine Injection. 1.5mg/kg infused over 4 hours, daily for 5 days. Six cycles.
Coramsine Injection. 1.5mg/kg infused over 4 hours, daily for 5 days. Six cycles.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000099527
Related Trials
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT0722741549 locations
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT059698602 locations
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT068633112 locations
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
NCT072395961 location
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
NCT057038541 location